【微创医疗(00853.HK)预计2024年度净亏损收窄超58%】微创医疗(00853.HK)发布公告,于截至2024年12月31日止12个月,尽管面对快速变化及愈发复杂的外部环境,尤其2024年下半年行业政策推出及市场环境变化,集团收入仍预计实现近10%的增长(该收入增长率及本公告所列示的收入增长率已剔除汇率影响),及取得净亏损不超过2.75亿美元,较上年同期亏损收窄超过58%。

金融界
07 Mar
微创医疗(00853.HK)发布公告,于截至2024年12月31日止12个月,尽管面对快速变化及愈发复杂的外部环境,尤其2024年下半年行业政策推出及市场环境变化,集团收入仍预计实现近10%的增长(该收入增长率及本公告所列示的收入增长率已剔除汇率影响),及取得净亏损不超过2.75亿美元,较上年同期亏损收窄超过58%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10